The APOE4 gene variant, an established genetic risk factor for Alzheimer’s disease, may also influence how toxic TDP-43 protein clumps spread in people with amyotrophic lateral sclerosis (ALS), a study suggested. Researchers found that people with ALS who carried the variant were significantly more likely to show TDP-43…
News
Outsee has been selected for a Discovery Award from the Longitude Prize on ALS to support the use of the company’s artificial intelligence (AI)-based platform and large-scale patient genomic data to identify new therapeutic targets for amyotrophic lateral sclerosis (ALS). The Longitude Prize on ALS is a £7.5…
Statins, medications designed to lower cholesterol, do not meaningfully alter the risk of death or disease progression in people with amyotrophic lateral sclerosis (ALS), according to a study. The researchers said the findings show that ALS itself should not influence doctors’ decisions about prescribing statins. Instead, statins should be…
Differences in the inflammatory activity of certain immune cells may explain why amyotrophic lateral sclerosis (ALS) progresses faster in some people than others, according to a study. The findings suggest that it may be possible to slow ALS progression by targeting specific inflammatory disease markers. “The intensity of spinal…
Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid formulation of NUZ-001, which the company is developing for amyotrophic lateral sclerosis (ALS), in healthy volunteers. A tablet version of NUZ-001 is being tested in a Phase 2/3 clinical…
An international team of scientists has developed an RNA-based experimental medicine that has the potential to reduce clumping of the TDP-43 protein, a key molecular feature of amyotrophic lateral sclerosis (ALS). The researchers determined, in precise molecular detail, how the RNA-based therapy interacts with the TDP-43 protein and showed…
Dutch Bros is holding its annual Drink One for Dane Day of Giving fundraiser this Friday, May 15, with the Dutch Bros Foundation and franchisees donating $1 from every drink sold to support the fight against amyotrophic lateral sclerosis (ALS). The event raises funds and awareness of…
COYA 302, Coya Therapeutics’ investigational therapy for amyotrophic lateral sclerosis (ALS) — shown in an early clinical trial to slow disease progression in a small number of patients — has been awarded fast track status by the U.S. Food and Drug Administration (FDA). That designation is intended to…
The ALS Association has awarded $3 million to help expand access to specialized amyotrophic lateral sclerosis (ALS) care in underserved and geographically isolated communities across the U.S. The funding comes from the organization’s Hoffman ALS Clinic Development and Capacity Awards programs, established through a historic $58 million…
A cellular recycling system that degrades damaged or unwanted proteins is impaired in motor neurons from people with amyotrophic lateral sclerosis (ALS), suggesting it could be a target for future therapies aimed at slowing disease progression, according to a new study. The research also showed that motor neurons in…
Recent Posts
- Treatment burden affects nearly 70% of ALS patients in Italian study
- Lower levels of two molecules linked to faster ALS progression, shorter survival
- This ALS caregiver is learning to hit the pause button
- Oral prosetin proves safe in early trial, paving way for Phase 2
- Adult children of parents with ALS may need more support, study finds